Ken Griffin Moon Lake Immunotherapeutics Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 1,674,041 shares of MLTX stock, worth $92.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,674,041
Previous 9,100
18296.05%
Holding current value
$92.7 Million
Previous $355,000
22157.46%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.8MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$1.09 Billion36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$230 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$145 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.43MShares$79.4 Million0.29% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...